- Oral presentation
- Open Access
Structures and activities of Drug and Therapeutic Committees in formulary management: findings from a national survey and key informant interviews
© Ramli et al; licensee BioMed Central Ltd. 2014
- Published: 29 January 2014
- Focus Group Discussion
- Drug Expenditure
- Drug Formulary
- Healthcare Institution
- Formulary Management
Drug expenditures continue to rise due to increasing disease burden and emergence of new drugs. World Health Organization (WHO) recommended that Drug and Therapeutic Committee (DTC) be set up in healthcare institutions to manage drug formularies and policies promoting rational drug selection and use. Operations of DTCs in MOH facilities are yet to be documented. This study was set to gain insights on DTCs particularly in exerting these roles.
A mixed method of focus group discussions (FGD), survey and semi-structured interviews was used. The FGDs provided basic information on DTC operations and formulary management in MOH facilities. Survey questionnaires were sent to all 136 MOH hospitals and 15 state health offices to obtain more detailed information. Seven key informants were interviewed to gain in-depth knowledge.
Altogether 118 completed questionnaires were returned (response rate: 78%). Almost all (97.5%) of the facilities had operational DTCs. However, they varied considerably in structures and activities. All DTCs were multidisciplinary consisting of mainly department heads with 3 to 36 members. There were 96 of 118 (81.4%) facilities who maintained local drug list that are subsets to the National Drug Formulary. Eighty-one (68.6%) of the DTCs lacked term of reference documents. Expected DTCs’ responsibilities were not clearly specified, often being assumed by pharmacy departments. The interviews highlighted that local DTCs’ fundamental agenda was managing individual institutions’ drug expenditures, supporting the survey findings that drug budget and procurements being the two most frequently discussed issues in DTC meetings. New applications to list new drugs into the national formulary often not debated much during local DTC meetings. The main reasons identified include inadequate resources to conduct drug evaluation and perceptions of overlapping roles with national level DTCs.
Suboptimal standardisation in structure and activities of MOH DTCs emphasises the need for national level coordination of individual DTC operations in formulary management roles.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.